Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma.
Silvennoinen R, Lundan T, Kairisto V, Pelliniemi TT, Putkonen M, Anttila P, Huotari V, Mäntymaa P, Siitonen S, Uotila L, Penttilä TL, Juvonen V, Selander T, Remes K. Silvennoinen R, et al. Blood Cancer J. 2014 Oct 10;4(10):e250. doi: 10.1038/bcj.2014.69. Blood Cancer J. 2014. PMID: 25303369 Free PMC article. Clinical Trial.
Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT.
Grövdal M, Nahi H, Gahrton G, Liwing J, Waage A, Abildgaard N, Pedersen PT, Hammerstrøm J, Laaksonen A, Bazia P, Terava V, Ollikainen H, Silvennoinen R, Putkonen M, Anttila P, Porkka K, Remes K. Grövdal M, et al. Among authors: silvennoinen r. Bone Marrow Transplant. 2015 Jun;50(6):808-12. doi: 10.1038/bmt.2015.39. Epub 2015 Apr 13. Bone Marrow Transplant. 2015. PMID: 25867654 Clinical Trial.
Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison.
Valtola J, Varmavuo V, Ropponen A, Nihtinen A, Partanen A, Vasala K, Lehtonen P, Penttilä K, Pyörälä M, Kuittinen T, Silvennoinen R, Nousiainen T, Pelkonen J, Mäntymaa P, Jantunen E. Valtola J, et al. Among authors: silvennoinen r. Transfusion. 2015 Oct;55(10):2358-68. doi: 10.1111/trf.13170. Epub 2015 May 28. Transfusion. 2015. PMID: 26018461 Clinical Trial.
A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma.
Silvennoinen R, Anttila P, Säily M, Lundan T, Heiskanen J, Siitonen TM, Kakko S, Putkonen M, Ollikainen H, Terävä V, Kutila A, Launonen K, Räsänen A, Sikiö A, Suominen M, Bazia P, Kananen K, Selander T, Kuittinen T, Remes K, Jantunen E. Silvennoinen R, et al. Bone Marrow Transplant. 2016 Mar;51(3):372-6. doi: 10.1038/bmt.2015.236. Epub 2015 Oct 5. Bone Marrow Transplant. 2016. PMID: 26437056 Free PMC article. Clinical Trial.
Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison.
Valtola J, Silvennoinen R, Ropponen A, Siitonen T, Säily M, Sankelo M, Terävä V, Putkonen M, Kuittinen T, Pelkonen J, Mäntymaa P, Remes K, Varmavuo V, Jantunen E. Valtola J, et al. Among authors: silvennoinen r. Transfusion. 2016 Jun;56(6):1394-401. doi: 10.1111/trf.13574. Epub 2016 Apr 4. Transfusion. 2016. PMID: 27041692 Clinical Trial.
Cost analysis of a randomized stem cell mobilization study in multiple myeloma.
Varmavuo V, Silvennoinen R, Anttila P, Säily M, Sankelo M, Putkonen M, Ahonen J, Mahlamäki E, Mäntymaa P, Savolainen ER, Remes K, Jantunen E. Varmavuo V, et al. Among authors: silvennoinen r. Ann Hematol. 2016 Oct;95(10):1653-9. doi: 10.1007/s00277-016-2772-1. Epub 2016 Aug 3. Ann Hematol. 2016. PMID: 27485453 Clinical Trial.
Impact of lenalidomide-based induction therapy on the mobilization of CD34+ cells, blood graft cellular composition, and post-transplant recovery in myeloma patients: a prospective multicenter study.
Partanen A, Valtola J, Silvennoinen R, Ropponen A, Siitonen T, Putkonen M, Sankelo M, Pelkonen J, Mäntymaa P, Varmavuo V, Jantunen E. Partanen A, et al. Among authors: silvennoinen r. Transfusion. 2017 Oct;57(10):2366-2372. doi: 10.1111/trf.14220. Epub 2017 Jul 5. Transfusion. 2017. PMID: 28681435
Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing.
Majumder MM, Silvennoinen R, Anttila P, Tamborero D, Eldfors S, Yadav B, Karjalainen R, Kuusanmäki H, Lievonen J, Parsons A, Suvela M, Jantunen E, Porkka K, Heckman CA. Majumder MM, et al. Among authors: silvennoinen r. Oncotarget. 2017 May 5;8(34):56338-56350. doi: 10.18632/oncotarget.17630. eCollection 2017 Aug 22. Oncotarget. 2017. PMID: 28915594 Free PMC article.
Blood graft composition and post-transplant recovery in myeloma patients mobilized with plerixafor: a prospective multicenter study.
Valtola J, Silvennoinen R, Ropponen A, Siitonen T, Säily M, Sankelo M, Putkonen M, Partanen A, Pyörälä M, Savolainen ER, Mäntymaa P, Pelkonen J, Jantunen E, Varmavuo V. Valtola J, et al. Among authors: silvennoinen r. Leuk Lymphoma. 2019 Feb;60(2):453-461. doi: 10.1080/10428194.2018.1485911. Epub 2018 Aug 30. Leuk Lymphoma. 2019. PMID: 30160591
71 results